Clinical Trial Update: Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update describes evaluation of BBI-355 (CHK1 inhibitor) in combination with BBI-825 (RNR inhibitor) for tumors with oncogene amplificat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anogenital Cancer
• Cervical Squamous Cell Carcinoma
• Cutaneous Squamous Cell Carcinoma
• Estrogen Receptor-positive Breast Cancer
• Head and Neck Squamous Cell Carcinoma
• High-grade Endometrial Cancer
• High-grade Serous Ovarian Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• BBI-355 (CHK1 inhibitor)
• BBI-825 (Ribonucleotide reductase inhibitor)

Snippet

Sponsor: Boundless Bio, Inc. | Conditions: Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING